Susie Suh

Susie Suh

Auto-generated profile, based on publicly available information

Susie Suh

University of California, Irvine

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2022 in Cell
Verified
Journal Article
Open access
SBSamagya Banskota
Samagya Banskota
ARAditya Raguram
Aditya Raguram
SSSusie Suh
Susie Suh
SDSamuel W. Du
Samuel W. Du
JDJessie R. Davis
Jessie R. Davis
DLDavid R. Liu
David R. Liu
Methods to deliver gene editing agents in vivo as ribonucleoproteins could offer safety advantages over nucleic acid delivery approaches. We report the development and application of engineered DNA-free virus-like particles (eVLPs) that efficiently package and deliver base editor or Cas9 ribonucleoproteins. By engineering VLPs to overcome cargo packaging, release, and localization bottlenecks, we developed fourth-generation eVLPs that mediate efficient base editing in several primary mouse and human cell types. Using different glycoproteins in eVLPs alters their cellular tropism. Single injections of eVLPs into mice support therapeutic levels of base editing in multiple tissues, reducing serum Pcsk9 levels 78% following 63% liver editing, and partially restoring visual function in a mouse model of genetic blindness. In vitro and in vivo off-target editing from eVLPs was virtually undetected, an improvement over AAV or plasmid delivery. These results establish eVLPs as promising vehicles for therapeutic macromolecule delivery that combine key advantages of both viral and nonviral delivery.

19 October 2020 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
SSSusie Suh
Susie Suh
ECElliot H. Choi
Elliot H. Choi
HLHenri Leinonen
Henri Leinonen
AFAndrzej T. Foik
Andrzej T. Foik
GNGregory A. Newby
Gregory A. Newby
KPKrzysztof Palczewski
Krzysztof Palczewski

28 February 2020 in International Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
SSSusie Suh
Susie Suh
CPChristine Pham
Christine Pham
JSJanellen Smith
Janellen Smith
NMNatasha Mesinkovska
Natasha Mesinkovska

5 April 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
ECElliot H. Choi
Elliot H. Choi
SSSusie Suh
Susie Suh
AFAndrzej T. Foik
Andrzej T. Foik
HLHenri Leinonen
Henri Leinonen
GNGregory A. Newby
Gregory A. Newby
KPKrzysztof Palczewski
Krzysztof Palczewski
Leber congenital amaurosis (LCA) is the most common cause of inherited retinal degeneration in children. LCA patients with RPE65 mutations show accelerated cone photoreceptor dysfunction and death, resulting in early visual impairment. It is therefore crucial to develop a robust therapy that not only compensates for lost RPE65 function but also protects photoreceptors from further degeneration. Here, we show that in vivo correction of an Rpe65 mutation by adenine base editor (ABE) prolongs the survival of cones in an LCA mouse model. In vitro screening of ABEs and sgRNAs enables the identification of a variant that enhances in vivo correction efficiency. Subretinal delivery of ABE and sgRNA corrects up to 40% of Rpe65 transcripts, restores cone-mediated visual function, and preserves cones in LCA mice. Single-cell RNA-seq reveals upregulation of genes associated with cone phototransduction and survival. Our findings demonstrate base editing as a potential gene therapy that confers long-lasting retinal protection.

1 June 2020 in Photodermatology, Photoimmunology & Photomedicine
Verified
Journal Article
Open access
PDF file
SSSusie Suh
Susie Suh
ECElliot H. Choi
Elliot H. Choi
NMNatasha Mesinkovska
Natasha Mesinkovska
Background: Skin is the organ most extensively exposed to light of a broad range of wavelengths. Several studies have reported that skin expresses photoreceptive molecules called opsins. However, the identity and functional role of opsins in the human skin remain elusive. We aim to summarize current scientific evidence on the types of opsins expressed in the skin and their biological functions.Methods: A primary literature search was conducted using PubMed to identify articles on dermal opsins found in nonhuman animals and humans.Results: Twenty‐two articles, representing, however, a non‐exhaustive selection of the scientific papers published in this specific field, met the inclusion criteria. In nonhuman animals, opsins and opsin‐like structures have been detected in the skin of fruit fly, zebrafish, frog, octopus, sea urchin, hogfish, and mouse, and they mediate skin color change, light avoidance, shadow reflex, and circadian photoentrainment. In humans, opsins are present in various skin cell types, including keratinocytes, melanocytes, dermal fibroblasts, and hair follicle cells. They have been shown to mediate wound healing, melanogenesis, hair growth, and skin photoaging.Conclusion: Dermal opsins have been identified across many nonhuman animals and humans. Current evidence suggests that opsins have biological significance beyond light reception. In nonhuman animals, opsins are involved in behaviors that are critical for survival. In humans, opsins are involved in various functions of the skin although the underlying molecular mechanisms remain unclear. Future investigation on elucidating the mechanism of dermal opsins will be crucial to expand the therapeutic benefits of photobiomodulation for various skin disorders.

19 September 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
SSSusie Suh
Susie Suh
ECElliot H Choi
Elliot H Choi
ARAditya Raguram
Aditya Raguram
DLDavid R. Liu
David R. Liu
KPKrzysztof Palczewski
Krzysztof Palczewski
CRISPR-Cas-based genome editing technologies could, in principle, be used to treat a wide variety of inherited diseases, including genetic disorders of vision. Programmable CRISPR-Cas nucleases are effective tools for gene disruption, but they are poorly suited for precisely correcting pathogenic mutations in most therapeutic settings. Recently developed precision genome editing agents, including base editors and prime editors, have enabled precise gene correction and disease rescue in multiple preclinical models of genetic disorders. Additionally, new delivery technologies that transiently deliver precision genome editing agents in vivo offer minimized off-target editing and improved safety profiles. These improvements to precision genome editing and delivery technologies are expected to revolutionize the treatment of genetic disorders of vision and other diseases. In this Perspective, we describe current preclinical and clinical genome editing approaches for treating inherited retinal degenerative diseases, and we discuss important considerations that should be addressed as these approaches are translated into clinical practice.